> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves GSK’s Measles Vaccine
- URL: https://www.fdaweb.com/fda-approves-gsks-measles-vaccine/
- Published: 2022-06-06T12:00:00.000Z
- Updated: 2026-09-14T17:47:29.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5151984

FDA has approved a GSK BLA for Priorix (measles, mumps and rubella vaccine) for use in individuals 12 months of age and older. The company notes that recently measles outbreaks have been rising in the U.S. and globally, “with more than 400,000 cases confirmed in 2019, reversing decades of progress toward measles elimination in many countries.” It says CDC data show that vaccine ordering in the past two years declined by 10%, indicating that fewer vaccinations in children were occurring. “Outbreaks of measles in recent years demonstrate how quickly diseases can return without widespread immunization,” the company says. “Missed vaccinations during the pandemic makes children even more vulnerable to vaccine-preventable diseases like measles.”   

Priorix’s approval was based on data from six clinical studies involving 12,151 participants, according to the company. The most commonly reported adverse reactions were pain, redness, swelling, loss of appetite, irritability, drowsiness and fever.